Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Want to cut your energy bills? Here’s how five experts are doing it 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
DURHAM, N.C., Feb. 28, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix, will present a corporate overview at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at http://ir.chimerix.com/events.cfm, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant unmet medical needs. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
